US 12,485,168 B2
Hepatitis B virus vaccines
Eric Bruening, San Francisco, CA (US); Janet Douglas, San Francisco, CA (US); Emily Marshall, San Francisco, CA (US); Karina Yusim, Santa Fe, NM (US); Bette Korber, Santa Fe, NM (US); and James Theiler, Santa Fe, NM (US)
Assigned to Vir Biotechnlogy, Inc., San Francisco, CA (US); and Triad National Security, LLC, Los Alamos, NM (US)
Appl. No. 17/638,344
Filed by Vir Biotechnology, Inc., San Francisco, CA (US); and Triad National Security, LLC, Los Alamos, NM (US)
PCT Filed Aug. 28, 2020, PCT No. PCT/US2020/048411
§ 371(c)(1), (2) Date Feb. 25, 2022,
PCT Pub. No. WO2021/045969, PCT Pub. Date Mar. 11, 2021.
Claims priority of provisional application 62/941,125, filed on Nov. 27, 2019.
Claims priority of provisional application 62/893,546, filed on Aug. 29, 2019.
Prior Publication US 2022/0288195 A1, Sep. 15, 2022
Int. Cl. A61K 39/29 (2006.01); A61K 39/00 (2006.01); A61P 31/20 (2006.01); C07K 14/005 (2006.01); C12N 15/86 (2006.01)
CPC A61K 39/292 (2013.01) [A61P 31/20 (2018.01); C07K 14/005 (2013.01); C12N 15/86 (2013.01); A61K 2039/5256 (2013.01); A61K 2039/53 (2013.01); A61K 2039/70 (2013.01); C12N 2710/16122 (2013.01); C12N 2710/16142 (2013.01); C12N 2730/10134 (2013.01)] 15 Claims
 
1. A polypeptide comprising the amino acid sequence as set forth in SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 14 15, 24, 25, or 26.